Johnson & Johnson braces for Q3 sales dip as generics bite

Johnson & Johnson (J&J) has warned that strong competition from generic drugs could impact the company’s figures for the rest of the year.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

J&J unit accuses rival of ‘shocking’ trade secrets theft

11 February 2021 A Johnson & Johnson unit has accused eye care product manufacturer Alcon of trade secrets theft, alleging that it had perpetrated “piracy of a nearly unfathomable scale” in ripping off a computer code.

Americas

J&J to buy surgical robotics company for $3.4bn

18 February 2019 Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.

Americas

J&J reveals plans to appeal cancer drug court ruling

29 October 2018 Johnson & Johnson has revealed its intention to appeal against a district court’s invalidation of a patent covering its prostate cancer drug Zytiga (abiraterone acetate).

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Johnson & Johnson braces for Q3 sales dip as generics bite

More on this story

Editor's picks

Editor's picks

More features